Home

Articles from Recordati

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
By Recordati · Via GlobeNewswire · April 28, 2025
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
By Recordati · Via GlobeNewswire · April 16, 2025
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
By Recordati · Via GlobeNewswire · February 13, 2025
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%
By Recordati · Via GlobeNewswire · November 8, 2024
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.
By Recordati · Via GlobeNewswire · October 4, 2024